Clinical Trials in Boston

Showing 11061-11080 of 15,299 trials

Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.

NCT01928797

The purpose of the study is to learn more about how the heart works during cesarean delivery under spinal anesthesia (medicines given in the spine that numb parts of your body to block pain) in women. The investigators would like to find out if the information about the heart can help in treating blood pressure changes that occur during the cesarean delivery. The investigators would also like to find out if this information can help reduce the chances of nausea and vomiting during the cesarean delivery. The activity of the heart changes during spinal anesthesia and cesarean section. In the past, a sensor placed directly into the heart was the only way to see how the heart worked. Currently, there are monitors that can sense the heart's activity via sensors that are placed on the skin during cesarean delivery. In this study, the investigators will use the ICON cardiac output (ICON) monitor. The ICON monitor is approved by the US Food and Drug Administration (FDA) to monitor (check) the activity of your heart. This study aims to: 1. Determine if additional cardiac output measurements help anesthesiologists maintain appropriate hemodynamics as defined as within 20% of baseline BP and if it changed their choice of vasopressors (primary outcome). 2. Determine if additional cardiac output measurements help to decrease the incidence of nausea and vomiting during cesarean delivery (secondary outcome).

Hypotension During Cesarean DeliverySpinal Anesthesia

Brigham and Women's Hospital60 participantsStarted Nov 2013

Boston, Massachusetts, United States

COMPLETEDNA< 1 mile

Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas

NCT01161862

The investigators hypothesize that our closed-loop glucose-control system can provide BG control in subjects with type 1 diabetes using the estimated BG signal from a CGM as the input signal to the controller.

Diabetes Mellitus

Boston University Charles River Campus24 participantsStarted Jul 2010

Boston, Massachusetts, United States

Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.

Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas

Find Trials by Condition in Boston

Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training

Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Extended Follow-Up After Islet Transplantation in T1D

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

Natural Evolution of AV Conduction Disorders in Patients Implanted With Cardiac Pacemakers

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (F.A.M.E.)